COVID-19/SARS-CoV S glycoprotein [CR3022] Antibodies

Recombinant monoclonal antibody to COVID-19 & SARS-CoV S glycoprotein.


  • Choose from human IgG1 or rabbit IgGk formats
  • Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e., specificity) from the hybridoma CR3022
  • Chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques

From our sister company Absolute Antibody.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
Anti-COVID-19/SARS-CoV S glycoprotein [CR3022] Human IgG1k Antibody
200ug In stock
Regular Price:$430.00
On Sale:
Anti-COVID-19/SARS-CoV S glycoprotein [CR3022] Rabbit IgGk Antibody
200ug In stock
Regular Price:$430.00
On Sale:

For larger sizes, please Contact Us for a bulk discount.


Product Type: Antibody
Name: Anti-COVID-19/SARS-CoV S glycoprotein [CR3022]
Alternative Name(s): Spike protein; COVID19; COVID 19; S protein; SARS-CoV S protein; S glycoprotein; E2; Peplomer protein; Spike protein S1; SARS Coronavirus; SARS-CoV-2; SARS CoV 2; 2019- nCoV
Accession ID: P59594
Antigen: COVID-19/SARS-CoV S glycoprotein
Source: Recombinant
Isotype: Human IgG1k or Rabbit IgGk
Clonality: Monoclonal
Clone Name: CR3022
Reactivity: SARS-CoV-2 (COVID-19) and SARS Coronavirus
Specificity: This antibody binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318Ð510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" confromation of the spike protein (Joyce et al. 2020)
Immunogen: The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV
Epitope: aa 318-510 of Spike protein
Purification Method: Protein A
Buffer: PBS, 0.02% Proclin 300
Tested Applications: crystallography, NTRL, SPR, ELISA
Concentration: 1 mg/mL
Storage: Store at +4C for up to 3 months. For longer storage, aliquot and store at -20C.
Shipped: Cold packs

From our sister company Absolute Antibody.
This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020).
  1. ter Meulen J, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3(7):e237.

If you publish research with this product, please let us know so we can cite your paper.